Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.

NCT02235987 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Acromegaly

Interventions

DRUG: octreotide
DRUG: DG3173

Sponsor

Aspireo Pharmaceuticals Limited